Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Hector Estepan

General Practice Lenoir, NC Medical Doctor

NPI 1124142369 CMS profile 232722

1345 Nc Highway 268, Lenoir, NC 28645

Open in the dashboard

General payments

$3,135

236 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Hector Estepan of Lenoir, NC is reported in the CMS Open Payments database as having received $3,135 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $345 21
2021 General $753 56
2020 General $864 71
2019 General $1,173 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hector Estepan
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Hector Estepan were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Hector Estepan General Practice median Middle half National median
2019 $1,173 $107 $37–$285 $163
2020 $864 $75 $25–$213 $114
2021 $753 $93 $30–$272 $132
2022 $345 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novo Nordisk Inc $587 47 payments
  2. AstraZeneca Pharmaceuticals LP $367 23 payments
  3. AbbVie, Inc. $334 25 payments
  4. Lilly USA, LLC $331 26 payments
  5. Pfizer Inc. $282 27 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $234 18 payments
  7. Sunovion Pharmaceuticals Inc. $213 16 payments
  8. Allergan Inc. $150 14 payments
  9. GlaxoSmithKline, LLC. $125 8 payments
  10. Sanofi-Aventis U.S. LLC $115 7 payments
  11. Other $397 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,126 234 payments
  2. Education $9 2 payments
Products named General payments · program years 2019–2022
  1. Ozempic $500 40 payments
  2. RYBELSUS $345 27 payments
  3. JARDIANCE $201 14 payments
  4. TRULICITY $181 13 payments
  5. LONHALA MAGNAIR $164 14 payments
  6. SYMBICORT $163 8 payments
  7. VRAYLAR $153 13 payments
  8. EUCRISA $150 17 payments
  9. ELIQUIS $149 11 payments
  10. Tresiba $145 12 payments
  11. Other $2,334 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record